



2th March

08:00 *Secretariat - Credentiation opening*

RENAL CELL CANCER

Chairman: JORGE OLIVEIRA – PEDRO OLIVEIRA – STEPHEN RIGGS

- 09:00 – 09:15 HISTOLOGICAL SUBTYPES AND TREATMENT
FERRAN ALGABA
- 09:15 - 09:30 THE PLACE OF TKI : STILL 1ST LINE IN METASTATIC RENAL CELL CANCER?
SÉRGIO BARROSO
- 09:30 – 09:45 COMBINATION THERAPY IN METASTATIC RENAL CELL CARCINOMA
LUIS COSTA
- 09:45 – 10:15 IMMUNOTHERAPY AND NEW TARGETED THERAPIES
ELISABETH HEATH
- 10:15 – 10:45 CLINICAL CASES
ANDRÉ MANSINHO
- DISCUSSION PANEL
JOSÉ NUNES MARQUES – ANTÓNIO ARAÚJO
- 10:45 – 11:05 *coffee-break*

BLADDER CANCER

Chairman: RUI HENRIQUE – ESTEVÃO LIMA – PAULO COSTA

- 11:05 – 11:20 PATHOLOGY REPORT IN BLADDER CANCER TO HELP THE BEST TREATMENT
CARLOS LOPES
- 11:20 – 11:40 HOW DO I TREAT HIGH-RISK SUPERFICIAL BLADDER CANCER
MAURIZIO BRAUSI
- 11:40 – 11:55 SURGERY ALONE IN INVASIVE BLADDER CANCER?
STEPHEN RIGGS

- 11:55 – 12:05 WHAT ABOUT NEOADJUVANT CHEMOTHERAPY IN INVASIVE BLADDER CANCER?
ELISABETH HEATH
- 12:05 – 12:15 WHAT ABOUT RADIO IN INVASIVE BLADDER CANCER
ANTHONY ZIETMAN
- 12:15 – 12:30 IS ADJUVANT CHEMOTHERAPY IN INVASIVE BLADDER CANCER - STATE OF THE ART,OR NOT?
DEREK RAGHAVAN
- 12:30 – 13:00 CLINICAL CASES
DEREK RAGHAVAN
- DISCUSSION PANEL
BELMIRO PARADA – ISABEL FERNANDES – JORGE OLIVEIRA
- 13:00 – 14:30 *Lunch*

PROSTATE CANCER

Chairman: CARLOS LOPES – FRANCISCO PINA – ELISABETH HEATH

- 14:30 – 14:45 PROSTATE BIOPSY: CONTEMPORARY CHALLENGES BEYOND DIAGNOSIS
RUI HENRIQUE
- 14:45 – 15:00 EPIDEMIOLOGY AND SCREENING
GABRIEL HAAS
- 15:00 – 15:15 STROMAGENIC CARCINOMA OF THE PROSTATE CANCER
BRIAN MILES
- 15:15 – 15:30 FUSION BIOPSY – MRI AND COMPLICATIONS
BASHAR OMABASHA
- 15:30 – 16:30 Q & A
EDSON PONTES – ARNALDO FIGUEIREDO
- 16:10 – 16:30 *Coffee-Break*

RENAL CELL CANCER

Chairman: NUNO VAU – MAURIZIO BRAUSI – ALEJO RODRIGUEZ-VIDA

- 16:30 – 16:55 NEW AVENUES IN IMMUNOTHERAPY
ALEJO RODRIGUEZ-VIDA
- 16:55 – 17:30 CLINICAL CASES
NUNO VAU
- DISCUSSION PANEL
HELDER MANSINHO – ANDRE MANSINHO
- 17:30– 17:45 CONCLUSIONS
- 17:45 – 18:45 POSTER evaluation (exhibition room)

INVASIVE BLADDER CANCER

Chairman: DEREK RAGHAVAN – F.CALAIS DA SILVA – EDSON PONTES

- 09:00 – 09:30 ARE THERE NEW INDICATIONS IN IMMUNOTHERAPY?
CORA STERNBERG
- 09:30 – 09:50 CLINICAL CASES
MÁRIO FONTES E SOUSA
- 09:50 – 10:15 DISCUSSION PANEL
FERNANDO FERRITO – HÉLDER MANSINHO
- 10:15– 10:40 *Coffee-Break*

INVASIVE BLADDER CANCER

Chairman: ANTÓNIO QUINTELA – MIGUEL BARBOSA - FRANCISCO BOTELHO

- 10:40 – 10:55 EVOLUTION OF THE PARADIGM IN THE TREATMENT OF ADVANCED UROTHELIAL CARCINOMA
ISABEL FERNANDES
- 10:55 – 11:20 CLINICAL EXPERIENCE WITH IMMUNOTHERAPY IN INELEGIBLE PATIENTS TO CISPLATIN AND AFTER CISPLATIN THERAPY
JOSE ANGEL ARRANZ
- 11:20 – 11:50 DISCUSSION PANEL
PEDRO MADEIRA– CARLOS RABAÇA

PENILE CANCER

Chairman: FERRAN ALGABA – LA FUENTE CARVALHO – STEPHEN RIGGS

- 11: 50– 12:05 FROM L.A.S.T. TO WHO TO SENTINEL LYMPH NODE: HPV IN PENILE CANCER.
PEDRO OLIVEIRA
- 12:05 – 12:20 LYMPHADENECTOMY: WHEN?
STEPHEN RIGGS
- 12:20 – 12:35 BRACHYTHERAPY: WHY AND WHEN?
ANTHONY ZIETMAN
- 12:35 – 13:00 CLINICAL CASES
STEPHEN RIGGS
- DISCUSSION PANEL
AUGUSTO PEPE CARDOSO – JOSÉ LA FUENTE CARVALHO
- 13:00 – 14:30 *Lunch*

PROSTATE CANCER

Chairman: DEREK RAGHAVAN – LUIS CAMPOS PINHEIRO – ARNALDO FIGUEIREDO

- 14:30 – 14:45 HOW DO I TREAT mCRPC?
ELISABETH HEATH
- 14:45 – 15:00 SURGERY VS RADIOTHERAPY IN HIGH-RISK DISEASE PROSTATE CANCER
STEPHEN RIGGS
- 15:00 – 15:15 CHEMOTHERAPY IS THERE A PLACE IN THE FUTURE?
DEREK RAGHAVAN
- 15:15 – 15:55 CLINICAL CASES
ELISABETH HEATH
- DISCUSSION PANEL
ESTEVAO LIMA – ANTONIO ARAUJO – MAURIZIO BRAUSI

PROSTATE CANCER

Chairman: PEDRO GOMES MONTEIRO – SÉRGIO BARROSO

- 15:55 – 16:10 NEW HORMONAL INDICATION IN HORMONAL SENSITIVE PROSTATE CANCER PATIENTS
PEDRO NUNES
- 16:10– 16:25 UPFRONT CHEMOTHERAPY IN HORMONAL PROSTATE CANCER PATIENTS? YES OR NO?
CHIARA RODRIGUES
- 16:25 – 16:50 DISCUSSION
FRANCISCO BOTELHO – MIGUEL BARBOSA – FERNANDO FERRITO

PROSTATE CANCER

Chairman: PAULO COSTA – EDSON PONTES – ANTHONY ZIETMAN

- 16:50 – 17:05 WHEN TO WATCH AND WAIT?
FRANCISCO PINA
- 17:05 – 17:20 CRYOTHERAPY: A VALID OPTION?
EDSON PONTES
- 17:20 – 17:35 WHAT'S NEW IN ANDROGEN RECEPTOR FUNCTION AND NEW AGENTS?
DEREK RAGHAVAN
- 17:35 – 17:50 RADIUM 223 & ADVANCES IN RADIOTHERAPY
ANTHONY ZIETMAN
- 17H50 – 18:10 DISCUSSION PANEL
PEDRO NUNES – FERNANDO MANUEL CALAIS DA SILVA

- 18:10 – 19:00 Poster evaluation (exhibition room)

MEETING ORGANIZERS

GPGU – Portuguese Genitourinary Group
Levine Cancer Institute / Carolinas Healthcare System

SCIENTIFIC BOARD

Fernando Calais da Silva – Chairman of the portuguese genitourinary group
Derek Raghavan – President of Levine Cancer Institute, Carolinas HealthCare System
University of North Carolina School of Medicine
Maurizio Brausi – Chairman of ESOU - EAU Section of Oncological Urology

INTERNATIONAL FACULTY

Alejo Rodriguez-Vida - IMIM Hospital del Mar Medical Research Institute - Barcelona
Anthony Zietman – Massachusetts General Hospital – Harvard Medical School
Bashar Omarbasha – Upstate Medical University – Syracuse
Brian Miles – Baylor School of Medicine and Methodist Hospital – Houston
Cora Sternberg - San Camillo and Forlanini Hospitals - Roma
Derek Raghavan – Levine Cancer Institute – Carolinas HealthCare System – UNC School of Medicine - Charlotte
Edson Pontes Karmanos Cancer center – Wayne State University School of Medicine – Detroit
Elisabeth Heath – Karmanos Cancer Institute – Wayne State University School of Medicine
Detroit
Ferran Algaba -Fundacio Puigvert – Barcelona
Gabriel Haas – Loyola University – Maywood
Jose Angél Arranz - HGU Gregorio Marañón - Madrid
Maurizio Brausi – Chairman ESOU - EAU Section of Oncological Urology
Pedro Oliveira – Christie Hospital – Manchester
Stephen Riggs – Levine Cancer Institute – UNC School of Medicine - Charlotte

PORTUGUESE FACULTY

Andre Mansinho – C.H.L.N. Hospital Santa Maria – Lisboa
António Araújo - C.H.P. Hospital Santo António – Porto
António Quintela – C.H.L.N. Hospital Santa Maria – Lisboa
Arnaldo Figueiredo -C.H.U.C. – Coimbra
Augusto Pepe Cardoso – Hospital Fernando da Fonseca - Amadora
Belmiro Parada C.H.U.C. – Coimbra
Carlos Lopes – ICBAS – Porto
Carlos Rabaça – I.P.O. – Coimbra
Chiara Rodrigues– C.H.L.C. Hospital dos Capuchos - Lisboa
Estevão Lima – Hospital Universitário – Braga
Fernando Ferrito – Hospital Fernando da Fonseca – Amadora
Fernando Manuel Calais da Silva – C.H.L.C. Hospital São José – Lisboa
Francisco Botelho – C.H.P. Hospital São João – Porto
Francisco Pina – C.H.P. Hospital São João – Porto

Helder Mansinho - Hospital Garcia de Orta – Almada
Isabel Fernandes - C.H.L.N. Hospital Santa Maria – Lisboa
José La Fuente Carvalho - C.H.P. Hospital Santo António - Porto
José Nunes Marques – C.H.L.O. Hospital São Francisco Xavier – Lisboa
Jorge Oliveira - I.P.O. – Porto
Luis Campos Pinheiro – C.H.L.C. Hospital São José – Lisboa
Luis Costa - C.H.L.N. Hospital Santa Maria – Lisboa
Mário Fontes e Sousa - I.P.O. – Porto
Miguel Barbosa – C.H.T.M.A.D. Hospital de Vila Real
Nuno Vau – Fundação Champalimaud – Lisboa
Paulo Costa – Hospital Universitário – Braga
Pedro Gomes Monteiro – C.H.L.O. Hospital Egas Moniz – Lisboa
Pedro Madeira - I.P.O. – Coimbra
Pedro Nunes – C.H.U.C. -Coimbra
Rui Henrique – I.P.O. – Porto
Sérgio Barroso – Clínica S.António - Amadora

POSTER JURY

Maria Joaquina Maurício -I.P.O.- Porto
Mario Reis – Prof. Agregado Jubilado - Porto
Filinto Marcelo – Clínica São Roque - Penafiel
Artur Gomes de Oliveira – Clínica de Oeiras, Hospital da Luz – Oeiras
Edson Pontes – Karmanos Cancer Center - Wayne State University School of Medicine - Detroit

SCIENTIFIC SPONSOR

Grupo Português
Génito - Urinário



Carolinas HealthCare System
Levine Cancer Institute

esou^{EAU}



ACCREDITATION



SPONSORS



Bristol-Myers Squibb

